In some cases, IFN-β therapy for relapsing-remitting multiple sclerosis (RRMS) has resulted in LN or thrombotic microangiopathy (Allinovi et al., 2017; Gianassi et al., 2019). This evidence concerns the gene IFNB1 and relapsing-remitting multiple sclerosis.